These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38063004)

  • 1. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study.
    Pujari S; Gaikwad S; Panchawagh S; Chitalikar A; Joshi K; Rohekar C; Dabhade D; Bele V
    AIDS Res Hum Retroviruses; 2024 Apr; 40(4):204-215. PubMed ID: 38063004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
    Walmsley S; Smith DE; Górgolas M; Cahn PE; Lutz T; Lacombe K; Kumar PN; Wynne B; Grove R; Bontempo G; Moodley R; Okoli C; Kisare M; Jones B; Clark A; Ait-Khaled M
    AIDS Res Ther; 2024 Mar; 21(1):17. PubMed ID: 38515183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
    Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
    Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
    Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
    Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
    Ibrahim F; Samarawickrama A; Hamzah L; Vincent R; Gilleece Y; Waters L; Kegg S; Barbini B; Campbell L; Post FA;
    HIV Med; 2021 Feb; 22(2):83-91. PubMed ID: 32985122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A; Chastek B; Gruber J; Majethia S; Zachry W; Mezzio D; Rock M; Anderson A; Cohen JP
    J Manag Care Spec Pharm; 2024 Aug; 30(8):817-824. PubMed ID: 39088337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
    van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
    Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
    Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
    HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life.
    Mejías-Trueba M; Gutierrez-Valencia A; Llaves-Flores S; Roca-Oporto C; Herrero M; Sotomayor de la Piedra C; Lopez-Cortes LF; Espinosa N
    Microbiol Spectr; 2024 Aug; 12(8):e0065424. PubMed ID: 38916326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
    Butler K; Anderson SJ; Hayward O; Jacob I; Punekar YS; Evitt LA; Oglesby A
    J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
    Campbell L; Ibrahim F; Barbini B; Samarawickrama A; Orkin C; Fox J; Waters L; Gilleece Y; Tariq S; Post FA;
    HIV Med; 2022 Apr; 23(4):362-370. PubMed ID: 34866304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
    BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
    Wei Y; Li J; Xu R; Wen L; Deng Y; He L; Zhong H; Wang Y
    Chin Med J (Engl); 2023 Nov; 136(22):2677-2685. PubMed ID: 37914678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.
    Katlama C; Bisshop F; Bogner J; Pérez Elías MJ; Di Giambenedetto S; Clarke E; Hodder S; Nwokolo N; Ait-Khaled M; Oyee J; Grove R; Wynne B; Okoli C; Jones B; Kisare M
    HIV Med; 2024 Jul; 25(7):873-884. PubMed ID: 38760011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.
    Underwood M; Urbaityte R; Wang R; Horton J; Oyee J; Wynne B; Fox D; Jones B; Man C; Sievers J
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.
    Calza L; Giglia M; Colangeli V; Bon I; Vitale S; Viale P
    HIV Med; 2024 Aug; 25(8):919-926. PubMed ID: 38570897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
    Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Cervo A; Valenti D; Callegaro A; Mussini C
    BMC Infect Dis; 2022 Oct; 22(1):782. PubMed ID: 36224538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.